What ABILITY Neurotech does

ABILITY Neurotech is a clinical-stage brain-computer interface (BCI) company developing a fully implantable, battery-free neural interface that decodes cortical activity into speech and movement in real time for patients with severe motor impairment. Spun out of the Wyss Center for Bio and Neuroengineering in Geneva in March 2025 with a $50 million founding investment, the company is building an end-to-end platform comprising a sub-5mm thin ECoG implant with 128 high-density electrodes, a proprietary laser-based 50 Mbps transcutaneous optical data link, a wearable headpiece and processor, a mobile patient-facing application, and an adaptive AI neural decoding engine. The platform is investigational and not commercially available; in May 2026 the company received Investigational Medical Device Dossier (IMDD) approval from the Dutch Medical Research Ethics Committee NedMec for its first chronic implantation study in ALS patients at UMC Utrecht, with parallel intra-operative studies at Technical University of Munich and consortium-based evaluation through the INTRECOM program with TU Graz and CorTec.

The company targets patients who have lost the ability to speak due to ALS, locked-in syndrome, or other severe motor disabilities, with the first clinical application being home-use speech restoration. Its pricing model is not yet disclosed and no commercial revenue exists; future commercialization is planned as B2B hardware sales to specialized BCI centers of excellence and neurology/ALS treatment hospitals, contingent on CE Mark and FDA clearance. The go-to-market motion is enterprise direct sales to a small number of high-specialization clinical centers, leveraging existing clinical-trial relationships. The company is positioning against larger competitors in the global BCI market, which third-party analysts estimate could reach $400 billion, with its differentiated bets being ECoG over penetrating electrodes, battery-free operation, and a lossless high-bandwidth optical link.

Name

ABILITY Neurotech

Legal name

ABILITY Neurotech

Website

https://abilityneuro.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

ABILITY Neurotech is a Geneva-based clinical-stage brain-computer interface company developing a fully implantable, battery-free ECoG device with proprietary 50 Mbps laser-based optical data transmission and AI neural decoding to restore speech in ALS and severely motor-impaired patients.

Ownership category

akta.pro rank

Product category

Neuroprosthetic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industries

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK), Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC)

Keywords

• Brain-computer interface
• Neuroprosthetic devices
• Implantable medical devices
• Neural decoding platform
• Speech restoration technology

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Brain-Computer Interface Medical Device Sales: ABILITY plans to commercialize its BCI platform as a medical device for restoring communication and speech in patients with severe motor impairment (e.g., ALS patients). Revenue will likely come from device sales and associated services to healthcare providers, pending regulatory approval (CE Mark, FDA clearance). Currently pre-revenue as the device is investigational and not commercially available.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

ABILITY Neurotech is developing and intends to commercialize an end-to-end, fully implantable, battery-free brain-computer interface (BCI) platform that restores communication, speech, and movement in patients with severe motor impairment such as ALS. The system combines a sub-5mm thin 128-channel ECoG implant, a wearable headpiece, a portable processor, and a patient-facing mobile app, all powered by an adaptive AI neural decoding engine that translates cortical signals into speech, text, and device control in real time via a proprietary 50 Mbps wireless optical data link through intact skin.

Product overview

ABILITY Neurotech offers a fully implantable brain-computer interface (BCI) platform for restoring communication and movement to patients with severe motor impairments. The platform consists of multiple integrated products: the ABILITY Implant (fully implantable ECoG-based device with 128 channels, battery-free operation, and 50 Mbps wireless optical data link), the ABILITY Headpiece (wearable external receiver), the ABILITY Processor (portable real-time decoding unit), the ABILITY App (mobile patient interface), and the ABILITY Neural Decoding Engine (AI-powered decoding software). The system captures complete raw neural data wirelessly through intact skin and decodes it into speech and movement in real time using adaptive AI that personalizes to each patient while learning from population-level data. The platform is electrode-agnostic by design, using high-density ECoG for speech applications. All components are investigational and not available for commercial use.

Differentiator

Problem solved

Functional benefit

Products and services

• ABILITY BCI Platform End-to-end speech neuroprosthesis platform comprising the ABILITY Implant, Headpiece, Processor, App, and Neural Decoding Engine. The system captures cortical activity via fully implantable ECoG electrodes and decodes it into natural speech and movement in real time, powered by adaptive AI. Targeted at healthcare institutions treating patients with severe motor impairment, initially ALS. Currently investigational and not available for commercial use.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core, supporting and foundational.

• UMC Utrecht (University Medical Center Utrecht)coreStrategic or Co-development Partner · 1 May 2026UMC Utrecht is the primary clinical trial site for ABILITY's first chronic implantation study in ALS patients. The trial is conducted under the INTRECOM consortium. Dr. Mariska Vansteensel serves as clinical lead. The center is a BCI center of excellence in the Netherlands.
• Technical University of Munich (TU Munich)coreStrategic or Co-development Partner · 1 May 2026TU Munich is conducting parallel intra-operative evaluation programs with ABILITY. This establishes a dual-track clinical strategy combining acute signal analysis (Munich) with chronic device performance assessment (Utrecht). TU Munich is a BCI center of excellence.
• Technical University of Graz (TU Graz)coreStrategic or Co-development Partner · 1 May 2026TU Graz is a partner in the INTRECOM consortium alongside UMC Utrecht, ABILITY Neurotech, and CorTec. The consortium enables multi-center clinical trials for the BCI platform in ALS patients.
• CorTecsupportingTechnology or Integration · 1 May 2026CorTec is a partner in the INTRECOM consortium, contributing to the collaborative clinical investigation of ABILITY's BCI platform. The consortium includes UMC Utrecht, TU Graz (Austria), ABILITY Neurotech, and CorTec.
• U.S. FDA (Breakthrough Device Designation)coreStrategic or Co-development Partner · 1 February 2026ABILITY submitted a Breakthrough Device Designation (BDD) request to the U.S. FDA, reserved for medical devices addressing serious unmet needs. BDD accelerates development, review, and patient access for the device.
• Wyss Center for Bio and NeuroengineeringfoundationalStrategic or Co-development Partner · 1 March 2025ABILITY Neurotech spun out from the Wyss Center for Bio and Neuroengineering in Geneva in March 2025. The company was built on years of pioneering BCI research conducted at the Wyss Center. Professor John Donoghue, the father of BCIs, was the founding director of the Wyss Center and designed the original system architecture.

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Boston Scientific: Major medical-device incumbent with Vercise DBS and growing neurotechnology portfolio. Comparable on neuromodulation infrastructure and global commercial reach into the neurology centers ABILITY would target.
• Abbott Neuromodulation: Incumbent neurotech player with FDA-approved DBS, spinal cord stimulation, and deep brain recording diagnostics. Comparable on regulatory maturity, clinical channel access, and implanted-neurology market positioning.
• Medtronic: Large incumbent medical-device company with significant neuromodulation franchise (DBS, SCS) and active investment in neurotechnology. Comparable as a broad player in implantable neurological devices and a potential strategic partner or acquirer for ABILITY's technology.

Direct peers

• Neuralink: Direct BCI peer developing implantable neural interfaces (N1 chip) for restoring speech, movement, and computer control. Competes head-to-head in the same fully implantable BCI category against ABILITY, with deeper capital and earlier FDA human-trial approval.
• Synchron: Direct BCI competitor using an endovascular stentrode approach to enable communication for patients with paralysis. Targets the same ALS/locked-in population as ABILITY and has received FDA IDE approval for human trials.
• Paradromics: Direct BCI competitor building a high-data-rate implantable brain-computer interface for speech restoration and neurological applications, with overlapping clinical and engineering approach to ABILITY's platform.
• Precision Neuroscience: Direct BCI peer developing a high-resolution cortical interface for speech decoding and digital control, with comparable clinical-stage implantable electrodes and similar target indications.
• Blackrock Neurotech: Direct BCI peer with long-standing implantable intracortical array technology used in academic human trials for speech and motor restoration. Competes on clinical-stage neural implant systems serving similar patients.

Emerging players

• BrainGate: Academic BCI research consortium (Brown / Stanford / MGH, etc.) demonstrating intracortical speech and motor BCIs in human patients. Comparable on scientific lineage and target applications; primarily research rather than commercial, but adjacent to ABILITY's market.

Others

• CorTec: Implantable electrode and electronics partner within the INTRECOM consortium alongside ABILITY at UMC Utrecht and TU Graz. Comparable as an enabling neurotechnology manufacturer and consortium collaborator in ABILITY's clinical trial.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ability-neurotech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ABILITY Neurotech